INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, June 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices.
On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred.
Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Rocket's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Rocket Pharmaceuticals class action, go to www.faruqilaw.com/RCKT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 hours ago
- Malaysian Reserve
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Aug. 12, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ('Summit' or 'the Company') (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the 'Class Period'), are encouraged to contact the firm before September 24, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Summit misled investors about the results of its Pinnacle Study of poziotinib, a potential treatment for lung cancer patients. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Summit, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law FirmBrian Schall, Esq., Office: 310-301-3335 info@
The Sun
16 hours ago
- The Sun
Wall Street stocks dip as chip sector reacts to China revenue-sharing deal
WALL STREET'S main indexes were down on Monday as investors await inflation data this week and chip companies seesawed after agreeing to share a portion of revenue from China sales with the U.S. under a trade policy shift from the Trump administration. Nvidia was flat after reversing premarket losses, and Advanced Micro Devices was up 0.5% in volatile trading. A U.S. official told Reuters the semiconductor majors had agreed to give the United States government 15% of revenue from sales of their advanced chips to China. Analysts said the levy could hit the chipmakers' margins and set a precedent for Washington to tax critical U.S. exports, potentially extending beyond semiconductors. 'A lot of people are not sure what to make of that because this is the first time in history that it's ever happened where an administration wants a percentage of the profits from a publicly traded company,' said Michael Matousek, head trader at U.S. Global Investors. Enabling semiconductor sales to China was an integral issue in the agreement Washington and Beijing signed this year, which expires on Tuesday. U.S. President Donald Trump lauded China's cooperation in talks at a White House press conference on Monday. At 2:01 p.m. ET (1801 GMT), the Dow Jones Industrial Average fell 176.88 points, or 0.40%, to 43,998.91, the S&P 500 lost 5.60 points, or 0.09%, to 6,383.93, and the Nasdaq Composite lost 12.87 points, or 0.06%, to 21,437.15. Traders took a step back after the S&P 500 and the Nasdaq last week logged their strongest weekly performances in more than a month. On Monday, the tech-heavy Nasdaq was on track for its third consecutive record closing high, if gains hold. Investors expect the recent shakeup at the U.S. Federal Reserve and signs of labor market weakness could nudge the central bank into adopting a dovish monetary policy stance later this year, fueling much of the optimism. July's consumer inflation report is due on Tuesday, and investors anticipate that the Fed will lower borrowing costs by about 60 basis points by December, according to data compiled by LSEG. 'Markets are on rate watch, so anything inflation-related will move markets this week,' said Jamie Cox, managing partner at Harris Financial Group. 'It's all about three rate cuts versus two at this point.' Citigroup and UBS Global Research became the latest brokerages to raise their year-end targets for the benchmark S&P 500. Micron Technology raised its forecast for fourth-quarter revenue and adjusted profit, boosting its shares 3%. Intel was up 3.5% after a report said CEO Lip-Bu Tan was expected to visit the White House. Trump had called for his removal last week. TKO jumped 8.5% after Paramount bought the rights from the live entertainment company to exclusively distribute UFC events for the next seven years in a deal valued at around $7.7 billion. Trump is expected to meet Russia's President Vladimir Putin on Friday to try and negotiate an end to Russia's war on Ukraine. Declining issues outnumbered advancers by a 1.11-to-1 ratio on the New York Stock Exchange. There were 203 new highs and 89 new lows on the NYSE. On the Nasdaq, declining issues outnumbered advancers by a 1.12-to-1 ratio. The S&P 500 posted 14 new 52-week highs and 15 new lows, while the Nasdaq Composite recorded 65 new highs and 98 new lows. - Reuters
New Straits Times
2 days ago
- New Straits Times
MCE eyes growth on Perodua EV, US expansion: HLIB
KUALA LUMPUR: MCE Holdings Bhd is set to enter a multi-year growth phase on the back of a landmark Perodua electric vehicle (EV) contract and expansion into the United States, according to Hong Leong Investment Bank (HLIB) Research. HLIB Research has initiated coverage on MCE with a "Buy" call and a target price of RM2.40, valuing the stock at 15 times its mid-FY27 partially diluted earnings per share of 16 sen. The firm described the auto parts supplier as a resilient, scalable play on Malaysia's shift towards high-value automotive electronics and the global 'China + N' supply chain realignment. MCE's entry into the EV segment comes through a high-value contract with Perodua to supply infotainment and advanced driver assistance system (ADAS) components, with revenue per vehicle at around RM3,000, about ten times its typical value. "With Perodua targeting an affordable launch price, we estimate MCE's annual revenue from this programme could amount to between RM39.8 million and RM59.7 million annually, or 26 per cent to 38 per cent of FY24 revenue, making it a powerful earnings catalyst," HLIB Research said. HLIB Research added that the company is accelerating its global expansion with two US wins for Nasdaq-listed Dorman in the automotive aftermarket and Michigan-based JVIS, a supplier to major original equipment manufacturers. The firm said the JVIS deal involves two multi-year mechatronics supply contracts worth RM91.7 million over five years, adding about RM18.3 million annually. Beyond automotive, MCE is expanding into new growth areas via multiple joint ventures, including a tie-up with Hong Kong's Sounding Industries to produce non-automotive products at its Johor facilities. The company also partnered with China's Nanjing Chuhang to produce ADAS mmWave radars at its upcoming Serendah plant, along with Chery-linked suppliers Cheling and Atech for participation in Chery's Malaysian localisation programme. MCE also formed a joint venture with India's Abhishek Electronics to tap into the fast-growing Indian automotive market. HLIB Research projects MCE's core earnings to grow at a compound annual growth rate of 15.8 per cent with estimated earnings for FY25, FY26 and FY27 reaching RM20.2 million, RM21.4 million and RM27 million, respectively. "FY26 growth will be driven by contribution from Dorman and the non-auto segment starting in the first half of FY26, with a stronger lift in the second half from Perodua's EV supply. "FY27 will see the full-year EV impact, maiden JVIS contribution and scaling of Dorman and non-auto has a robust balance sheet with a net cash position of RM83.6 million, equivalent to 59.8 sen a share, around 42 per cent of market capitalisation," the firm added. HLIB Research said years of investment in engineering and technology now position MCE to ride structural shifts in Malaysia's automotive industry towards localisation, high-value electronics and EV adoption, while benefiting from global supply chain diversification. It added that the company offers a resilient, scalable play on the sector's long-term transformation, anchored by stable demand from Proton and Perodua, as well as expansion via high-margin electronics, exports and strategic JVs.
